Congestive Heart Failure CHF and Cardiomyopathy

Home » DEPLOYMENT PROCESS » DEPLOYMENT PROTOCOLS » Congestive Heart Failure CHF and Cardiomyopathy

Congestive heart failure CHF is responsible for one million hospitalizations in the U.S. and considered the main cause or contributor to 53,000 deaths each year in the United States. CHF is associated with cardiomyopathy. Cardiomyopathy (deterioration in heart muscles) is commonly caused by coronary vessel disease but can also be due to infection and other causes. In this condition, the heart loses its ability to pump blood efficiently.

Cell therapy potentially offers an important solution for CHF and cardiomyopathy. During cardiac ischemia, millions of myocytes are lost resulting in loss of contractile function. One of the great goals of regenerative medicine is to engineer methods of replacing these cells. Bone marrow derived mesenchymal stem cells and now recently adipose derived mesenchymal stem cells appear to be playing an important role in this regeneration. There is also a growing body of data supporting the use of engineered biologics such as selected cell populations, organic scaffolds, and modified (differentiated or de-differentiated) stem cells to regenerate damaged myocardium. It is unknown whether the cost of engineered biologics over harvested stem cells is justified until long term studies are available. The results of clinical trials of the use of adult mesenchymal stem cells to treat cardiac disease have demonstrated safety and most have shown positive clinical results. Mesenchymal stem cells have been deployed intravenously, injected the myocardium, and placed in the coronary arteries and it is still unclear if one delivery method is clearly superior to another. It is also unclear which source of mesenchymal cells is optimal for cardiac regeneration but adipose derived cells appear to be highly effective in this area.

Congestive Heart Failure CHF, Cardiomyopathy and Carolina Stem Cell Treatment Center

Research has been ongoing around the world that exploits the anti-inflammatory and regenerative properties of adult stem cells to mitigate heart failure. Carolina Stem Cell Treatment Center and CSN are investigating the effects of SVF (rich in mesenchymal stem cells and growth factors) on CHF. We use a protocol designed by our interventional cardiologist that includes intravenous deployment. The CSCTC deployment protocol is performed under local anesthesia and is all done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately 3 hours.

Carolina Stem Cell Treatment Center Call to Action

We care about our congestive heart failure CHF and Cardiomyopathy patients at Carolina Stem Cell Treatment Center an affiliate of CSN. We take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals. By filling out the CSCTC Confidential Candidate Application, we will answer the questions and concerns you may have about CSCTC and CSN protocols for congestive heart failure CHF and Cardiomyopathy.